X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Total Equity
ÂĄ1.9B
CAGR 3-Years
23%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Equity
ÂĄ25.1B
CAGR 3-Years
0%
CAGR 5-Years
16%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Equity
ÂĄ12.7B
CAGR 3-Years
71%
CAGR 5-Years
57%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Equity
ÂĄ30.7B
CAGR 3-Years
6%
CAGR 5-Years
22%
CAGR 10-Years
24%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Equity
ÂĄ31.5B
CAGR 3-Years
32%
CAGR 5-Years
47%
CAGR 10-Years
29%
Imeik Technology Development Co Ltd
SZSE:300896
Total Equity
ÂĄ6.3B
CAGR 3-Years
12%
CAGR 5-Years
74%
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Total Equity?
Total Equity
1.9B CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Total Equity amounts to 1.9B CNY.

What is Xiamen Amoytop Biotech Co Ltd's Total Equity growth rate?
Total Equity CAGR 5Y
30%

Over the last year, the Total Equity growth was 33%. The average annual Total Equity growth rates for Xiamen Amoytop Biotech Co Ltd have been 23% over the past three years , 30% over the past five years .

Back to Top